Novo-Nordisk A/S (NVO) Financials
Key financial figures for Novo-Nordisk A/S (Q2 2026), as reported in DKK.
Novo Nordisk A/S reported revenue of 78.49 billion DKK for Q2 FY2026, up 2.1% from the same period a year earlier. Net income was 20.99 billion DKK, or 4.74 DKK per share. Operating margin came to 34.48%, against 43.52% a year earlier. Free cash flow for the period was 42.40 billion DKK. Across the last 5 reported quarters, quarterly revenue has risen from 76.86 billion DKK in Q2 FY2025 to 78.49 billion DKK in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Novo Nordisk A/S are on the SentiSense financials page.
- Revenue
- DKK 78.5B
- Net Income
- DKK 21.0B
- EPS
- DKK 4.74
- Total Assets
- DKK 594.9B
- Operating Cash Flow
- DKK 55.2B
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | DKK 78.5B | DKK 21.0B | DKK 4.74 | 34.48% | DKK 42.4B |
| Q1 FY2026 | DKK 96.8B | DKK 48.6B | DKK 10.91 | 61.57% | DKK 12.0B |
| Q4 FY2025 | DKK 79.1B | DKK 26.9B | DKK 6.04 | 40.1% | -DKK 36.2B |
| Q3 FY2025 | DKK 75.0B | DKK 20.0B | DKK 4.50 | 31.59% | DKK 30.7B |
| Q2 FY2025 | DKK 76.9B | DKK 26.5B | DKK 5.96 | 43.52% | DKK 24.5B |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | DKK 309.1B | DKK 102.4B | DKK 23.03 | 41.3% | DKK 29.0B |
| FY2024 | DKK 290.4B | DKK 101.0B | DKK 22.63 | 44.19% | DKK 69.7B |
| FY2023 | DKK 232.3B | DKK 83.7B | DKK 18.62 | 44.16% | DKK 70.0B |
Frequently asked questions
What was Novo Nordisk A/S's revenue last quarter?
Novo Nordisk A/S reported revenue of 78.49 billion DKK for Q2 FY2026, up 2.1% from the same period a year earlier.
Is Novo Nordisk A/S profitable?
Yes. Novo Nordisk A/S reported net income of 20.99 billion DKK for Q2 FY2026, a net margin of 26.74% on revenue.
How has Novo Nordisk A/S's margin trended?
Operating margin was 34.48% in Q2 FY2026, compared with 43.52% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Novo Nordisk A/S generate?
Novo Nordisk A/S generated free cash flow of 42.40 billion DKK in Q2 FY2026, after capital expenditure.
Figures are as reported by the filer in DKK and are not converted to US dollars. The share price is quoted in US dollars, so the two are not directly comparable.
Full income statement, balance sheet and cash flow for Novo-Nordisk A/S on SentiSense, with up to forty quarters and twenty fiscal years of history.